Isoprinosine Research Articles

Оценка вирусной нагрузки у пациенток с ВПЧ-ассоциированным цервицитом в процессе комплексного лечения

The article presents information about examination and treatment of the 39 women with chronic cervicitis associated with papillomavirus infection (HPV). Inosine pranobex is a drug with immunostimulating and anti-inflammatory action. It was used in the complex treatment of the patients. Patients were given 3 courses of inosine pranobex in a daily dose of 3000 mg with an interval of 10 days. Efficacy of the therapy was evaluated on the basis of clinical data, PAP-test, colposcopy, PCR - determination of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 types, as well as viral load of HPV before and after treatment. In 41.03±7.88% of patients who had a cytological picture of ASCUS, LSIL, HSIL, the concentration of HPV was clinically significant. Among the different types of HPV with high oncological risk, HPV types 16 and associations of different types of HPV prevailed in patients (p<0.05, p1<0.05). As a result of the use inosine pranobex in the complex treatment the viral load decreased to a clinically insignificant virus concentration in 17.95% of women, and HPV elimination occurred in 74.36% of patients.

Показания и опыт применения инозина пранобекса в педиатрической практике

Показания и опыт применения инозина пранобекса в педиатрической практике

Вирусные инфекции и репродуктивное здоровье

In a following review evidence on the role of genital viral infections in the development of reproductive system of women and men, their influence on fertility and reproductive losses is presented. It reflects the role of immunomodulatory therapy in the treatment of viral infections of the genital, in particular, inosine pranobex. The conclusion about the need for timely diagnosis, prevention and effective treatment of viral genital infections in both women and men during the clinical examination of the general public and especially at the stage of preparation pregravid couples is also made clear.

Инозин пранобекс: возможности этиотропной терапии при острой респираторной инфекции у детей

Инозин пранобекс: возможности этиотропной терапии при острой респираторной инфекции у детей

Инозина пранобекс в этиотропной терапии острых респираторных вирусных инфекций у часто болеющих детей

Инозина пранобекс в этиотропной терапии острых респираторных вирусных инфекций у часто болеющих детей

ROLE OF INOSINE PRANOBEX IN MANAGEMENT OF HPV-ASSOCIATED DISEASES: PROBLEMS AND PROSPECTIVE

The prevalence of HPV in Russia and the world is quite high, although epidemiological data are limited because morbidity rate of papillomatosis, particularly genital warts, are not clear. The most effective method of preventing infection is vaccination against HPV infection. One of the most effective preventive measure to reduce the risk of death from HPV-related cancer diseases is a regular screening. None of the treatments of HPV infection will not totally effective and will not prevent disease transmission. In most cases, treatment is aimed at getting rid of symptoms but not cure infection. Immunomodulators for management of HPV-associated diseases could not have evidence base. Clinically proven treatment with inosine pranobex eliminates HPV to 98% cases and 3 times reduce frequency of relapses in combined therapy. Correct and complete counseling, aimed at informing the patient about the connection of HPV infection and cancer, as well as the possibility of preventing infection by timely vaccination and proper compliance are issue at present time. Isoprinosine saves a woman from the HPV, reducing the possibility of recurrence and malignancy, only when patient has complete course of therapy.

ACUTE RESPIRATORY INFECTIONS IN CHILDREN: PROBLEM OF POLYPHARMACY

The authors sum up literature data concerning clinical effectiveness of antiviral and immunomodulating drug Inosine Pranobex in therapy of respiratory infections in children. The manifold effect of the drug allows preventing polypharmacy and render effective aid.

Acute and Recurrent Respiratory Tract Infections: Possible Reduction of the Patient’s Pill Burden

Acute and recurrent respiratory tract infections in children are often the reason for seeking medical help. Frequent and prolonged respiratory infections in childhood may lead to the subsequent formation of chronic respiratory diseases in adults. Susceptibility to respiratory infections is common in children with allergic diseases and other chronic diseases accompanied by a decrease in immune reactivity. In the case of acute respiratory infection, these patients, in addition to the basic treatment of the underlying disease, have to take additional cough medicines that increase the pill burden on the body. The main causative agents of acute respiratory infections are viruses. Inosine pranobex is a drug with antiviral and immunomodulatory effects. The article describes the pharmacological properties and the results from studying the efficacy of inosine pranobex in the treatment of acute respiratory viral infections in children.

Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes.

Inosine pranobex (inosine dimepranol acedoben, isoprinosine) (Inos) is an immunomodulatory and antiviral drug used in some viral infections, especially in patients with weakened immunity. In the present study, effects of Inos on the production of cytokines attributable to Th1 (IL-2, IFN-g, and TNF-a) or Th2 cells (IL-4, IL-5, and IL-10) were tested in human peripheral blood lymphocyte cultures stimulated with phytohemagglutinin (PHA). Inos enhanced TNF-a secretion significantly (in short-term--24-hour, and prolonged term--72-hour cultures) and IFN-g (in 72-hour cultures). Surprisingly, production of IL-10 by PHA-stimulated lymphocytes was suppressed by Inos in a dose-dependent manner in both 24-hour and 72-hour cultures. These results shed some light on immunomodulatory properties of Inos and suggest applicability of this agent in patients with a depressed function of the immune system.

Inosine Pranobex (Isoprinosine) – a Potential Adjuvant in the Management of Chronic HBV Infection

Inosine Pranobex (Isoprinosine) – a Potential Adjuvant in the Management of Chronic HBV Infection

Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro.

There are no specific antivirals designed for adenoviral infections. Due to many cases of adenovirus infections worldwide, epidemic nature of some types of adenoviruses, and growing number of patients with severe adenoviral infections resulting from dysfunction the immune system, the need for searching an effective and safe therapy is increasing. Inosine pranobex exerts antiviral effects which are both direct and secondary to immunomodulatory activity. In the present study we evaluated in vitro effect of inosine pranobex and interferon α (IFN-α) on replication of HAdV-2 and HAdV-5. The effectiveness of inosine pranobex under these conditions has not been previously reported. In conducted study we reported that inosine pranobex reduced the titer of infectious HAdV-2 and HAdV-5 in vitro. Higher concentrations of IP strongly inhibited multiplication of viruses. Combination of inosine pranobex and IFN-α display higher efficacy than either treatment alone and suggest that both agents may increase therapeutic effectiveness without augmenting toxic effects. Combination index calculations showed that inosine pranobex and INF-α synergistically inhibit HAdV-2 and HAdV-5 titers in A549 cells.

The Effectiveness of Complex Use of Inosine Pranobex and Recombinant Interferon-

The purpose of research — improvement of treatment programs for chronic Epstein-Barr virus mono-infection and mixed with clamidiosis infection in frequently ill children with use of inosine pranobex (isoprinosine) and recombinant interferon-a2b (viferon). Clinical, serological and immunological examination of 116 patients aged from 3 to 6 years with chronic Epstein-Barr virus infection in the form of mono-infection (48) and mixed with clamidiosis infection (68) is conducted. In the complex therapy of 24 children with mono-infection and 42 patients with mixed infection, inosine pranobex in combination with recombinant interferon-a2b were included. In 24 patients with mono-infection and 26 children with mixed infection, using only recombinant interferon-a2b. In patients with monoinfection, multiorgan pathology (respiratory, lymphoproliferative, cardial, cerebral, arthralgiс syndromes) was found. During serological examination found markers of active Epstein-Barr virus infection (IgM to VСA, IgG to EA, a high level of IgG to EBNA). Changes of the immune status was associated with activation of immune system (increase of CD8, HLA-DR, CD16, IgA, IgM, IgG, metabolic activity of neutrophils) and its damage (reduction of CD3, CD4, CD25, CD20, interferon-a, interleukin-4, reserve possibilities of neutrophils metabolism, increase of CD95, circulating immune complexes). Development of mixed infection led to a deepening of immunological disorders and increased frequency of respiratory, gastrointestinal and lymphoproliferative syndromes. When combined inosine pranobex and recombinant interferon-a2b was going to potentiation antiviral, of immunomodulatory and cytoprotective activity of drugs that reduced the incidence of acute respiratory infections and severity of multiorgan pathology. High efficiency and safety of inosine pranobex and recombinant interferon-a2b combination allow to recommend its inclusion in the complex therapy of patients from frequently ill children group with various forms of chronic Epstein-Barr virus infection.

Immunomodulating therapy and respiratory viral infections: an immunologist's point of view

This aim of this review was an analysis of rational approaches to development and implementation of immunomodulating drugs for therapy of respiratory infections. One of the most explored immune substances is inosine pranobex (Groprinosin). Inability to control many infectious diseases effectively using chemotherapeutic drugs determined the need to search for alternative methods based particularly on modulation of the immune system. Rational approaches to immune therapy of respiratory infections have been analyzed in this review. Groprinosin could be used for prevention and therapy of respiratory infections. Reasonable algorithms involving this agent have been demonstrated.

Дисфункции иммунитета при респираторных заболеваниях: нужны ли иммуномодуляторы у часто болеющих детей?

Insufficient control of many infectious diseases using etiotropic drugs determines the relevance of a search for alternative methods, in particular based on the modulation of the immune system. The review of recent literature analyzes rational approaches to the immunity dysfunction in frequently ill children. Attention is drawn to the fact that the use of immunomodulators reduces the frequency and severity of respiratory diseases and prevents complications. The article examines the advantages of the use of inosine pranobex that combines the properties of an immunomodulator and a direct antiviral activity. It is shown that inosine pranobex can be used for the prevention and treatment of respiratory infections in frequently ill children, and the rational schemes of its application are presented.

Оценка эффективности комплексной терапии патологии шейки матки, ассоциированной с папилломавирусной инфекцией

A comprehensive examination and treatment using the drug inosine pranobex (Isoprinosine), was performed on 123 patients with cervical pathology associated with human pathology virus (HPV). The study of the structure of the microbial landscape in patients with cervical pathology showed that among types of HPV with high statistical significance the HPV type 16 prevailed, the second highest rate spread was HPV 18. Inclusion of Isoprinosine complex therapy in patients with CIN I (LSIL, at virus load of 3 Lg/10¥5) was not required to further degrade the pathological process of the cervix , in 96.23±2.62% of cases, and contributed to the positive effect in total of 91.06% of patients with pathology of the cervix, which is statistically significant.

Could Inosine pranobex and Ribavirin in combination restore immune competence in chronic HCV advanced liver disease?

Could Inosine pranobex and Ribavirin in combination restore immune competence in chronic HCV advanced liver disease?

Противовирусная терапия острых респираторных инфекций у детей

Показано, что прием препарата инозин пранобекс ослабляет симптомы острой респираторной вирусной инфекции, сокращает время болезни, предотвращает осложнения и восстанавливает ­ослабленный иммунитет. Препарат эффективен не только в первые часы развития заболевания, но и в последующий период.

Validated Analytical Method Development of Inosine Pranobex in Drug Products by Thin Layer Chromatography

Thin layer chromatography (TLC) with densitometry has been established for the identification and the quantification of inosine pranobex in drug substance and drug products. Inosine pranobex is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol. UV densitometry was performed in absorbance mode at 260 nm. The separation was carried out on aluminum sheet of silica gel 60 f 254 [chloroform - methanol- - toluene -10% ammonia solution (6:5:1: 0.1% v/v)] as mobile phase. Linearity range was found to be 1-12, 2-12, 2-20 and 2-16 µg/ml for inosine pranobex, inosine, acetamidobenzoic acid, and dimethylaminoisopropanol with the mean percentage recoveries 99.74± 1.73%, 99.88 ± 1.75%, 99.56 ±1.08%, and 99.36 ± 0.71% respectively, (Correlation coefficient r2 = 0.9998 for inosine pranobex, r2 = 0.09999 for inosine, r2 = 0.9998 for acetamidobenzoic acid and r2= 0.9998 for dimethylaminoisopropanol). The detection and quantification limits for inosine pranobex and other components are also reported. The presented method was validated according to ICH guidelines. Statistical comparison of the results was performed using Student's t-test and F-ratio at 95% confidence level, and there was no significant difference between the reference and proposed method with regard to accuracy and precision. It could be said that the validated TLC-densitometry method is suitable for the routine analysis of inosine pranobex in quantity control laboratories.

Тактика ведения пациенток с заболеваниями шейки матки при персистирующей ВПЧ-инфекции: возможности комбинированного лечения

Understanding the persistence of HPV infection in cervical epithelium and associated development of benign diseases defines the tactics and treatment of cervical lesions associated with HPV.The Aim. To study the efficacy and long-term results of treating the benign cervical disease with persistent HPV infection when using the drug in combina-tion with Isoprinosine surgically.Material and methods: 80 patients with persistent HPV infection and cervical diseases. Combination therapy included: antiviral treatment of HPV infection (inosine pranobex) treatment aimed at the elimination of concomitant opportunistic microflora, yeasts and other microorganisms, radio frequency destruction, restoration of vaginal biocenosis. Determining factor in the choice of surgical intervention were the following factors: cytological and colposcopic data research methods; the presence or absence of a pathological process involving the cervical canal.The Results. Combination antiviral therapy in conjunction with radio wave surgery of benign cervical disease shows patients with persistent HPV infecion, have LSIL and HSIL, quantitative test positive for HPV, and had undergone previous surgical treatment of cervical other methods.

Therapeutic perspectives of recurrent respiratory infections

Viruses can cause interferon imbalance and inhibit cellular and phagocytic responses. Persistent viral and bacterial infections, such as Mycoplasma, Chlamydia, etc., can stimulate atopy and cause exacerbations of chronic respiratory diseases. A high efficacy of inosine pranobex (Groprinosin) has been demonstrated for treatment and prevention (immunological rehabilitation) of recurrent respiratory viral infections in adults and children.